SLC5A2 and depressive symptom measurement: However, no strong evidence suggesting colocalization between SGLT2 inhibition and depression (probability of sharing the same causal variant: 0.54%), anxiety disorder (probability: 6.61%), or bipolar affective disorder (probability: 5.65%) was observed (Table S6).